FDA Approves First Once-Weekly Insulin for Type 2 Diabetes Mellitus in Pediatric Patients

Synopsis

Awiqli lowers blood glucose over a weekly dosing interval. The safety profile of Awiqli is similar to that of other insulin products.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.